Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02932332 · ClinicalTrials.gov registry record · Phase 2

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

A Phase 2 study of Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target
1
Study location

NCT02932332: Completed Phase 2 study of Cancer, sponsored by M.D. Anderson Cancer Center.

NCT02932332 is a Phase 2 study of Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02932332, a Phase 2 study of Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to compare high-flow oxygen, low-flow oxygen, high-flow air, and low-flow air in helping to decrease shortness of breath in cancer patients. Researchers also want to learn if these therapies can help to improve lung function and quality of life.

Conditions Studied

Interventions

  • OTHER High-flow Oxygen
  • OTHER Low-flow Oxygen
  • OTHER High-flow Air
  • OTHER Low-flow Air

Study Locations (1)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2016-10-11
Est. Completion 2023-03-23
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT02932332

The ClinicalTrials.gov registry entry for NCT02932332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which High-flow Oxygen is the first listed.

NCT02932332 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02932332 about?

NCT02932332 is a clinical study titled "High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients". The goal of this clinical research study is to compare high-flow oxygen, low-flow oxygen, high-flow air, and low-flow air in helping to decrease shortness of breath in cancer patients. Researchers also want to learn if these therapies can help to improve lung function and quality of life.

What is the current status of trial NCT02932332?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-10-11. Estimated completion is 2023-03-23.

What conditions does trial NCT02932332 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT02932332?

The interventions under investigation include: High-flow Oxygen (OTHER), Low-flow Oxygen (OTHER), High-flow Air (OTHER), Low-flow Air (OTHER).

Who is sponsoring clinical trial NCT02932332?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02932332 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.